Testing empagliflozin for adults with type 2 diabetes on tablets
Treatments studied
Part of Hormones & metabolism clinical trials.
This study looks at how well and how safely empagliflozin works in real-world care for adults with type 2 diabetes who are not controlled on current pill treatment. Some participants take it with metformin, and the study helps confirm what to expect in everyday patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to 65 and have type 2 diabetes.
- Your recent A1C (a blood sugar average) is between 7% and 10%.
- Your diabetes is not well controlled despite oral diabetes pills and lifestyle changes for at least 3 months.
- You have not taken empagliflozin before.
- Your kidney function (eGFR) is above 60.
- You can sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called empagliflozin (a type 2 diabetes pill) to see how well it works in people with type 2 diabetes who have not taken any diabetes drugs for at least 8 weeks. If you qualify, you may receive the study drug and help researchers learn more about managing blood sugar.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
This trial tests whether adding empagliflozin (a diabetes pill) to your current medicines (alogliptin and metformin) helps manage blood sugar better. It may be an option if your blood sugar is not well controlled with your current treatment.
This trial tests a medicine called empagliflozin (usually used for diabetes) to see if it can help people with very advanced kidney disease and diabetes. The study will check if this drug can slow down further kidney damage and improve overall kidney health.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
This study tests whether a medication called empagliflozin (a diabetes drug) can improve heart function in older adults with high blood pressure and obesity who are at risk for heart failure but do not have it yet. You would take the pill daily and have heart ultrasounds to check your heart's health.
Hear when a new Safety Issues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.